Predictors of regional nodal disease in patients with thin melanomas

Annals of Surgical Oncology

Volumn 13, Issue 4, 2006, Pages 533-541

  Karakousis, Giorgos C ^a   Gimotty, Phyllis A ^a   Botbyl, Jeffrey D ^a   Kesmodel, Susan B ^a   Elder, David E ^a   Elenitsas, Rosalie ^a   Ming, Michael E ^a   Guerry, DuPont ^a   Fraker, Douglas L ^a   Czerniecki, Brian J ^a   Spitz, Francis R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Mitotic rate; Regional nodal disease; Thin melanomas; Ulceration; Vertical growth phase

Indexed keywords

ADULT; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; LYMPH NODE METASTASIS; MALE; MEDICAL ASSESSMENT; MELANOMA; MITOSIS RATE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; SENTINEL LYMPH NODE BIOPSY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MITOSIS; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; SENTINEL LYMPH NODE BIOPSY; SEX FACTORS; SKIN NEOPLASMS; TIME FACTORS;

EID: 33644983196     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.05.011     Document Type: Article

References (32)

1. Surveillance, Epidemiology, and End Results (SEER) Program. Public-use data (1973-2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Released April 2004. Based on the November 2003 submission. Available at: http://www.seer.cancer.gov/publicdata.
2. Reintgen D, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patient with malignant melanoma. Ann Surg 1997; 225:1-14.
3. Woods JE, Soule EH, Creagan ET. Metastasis and death in patients with thin melanomas (less than 0.76 mm). Ann Surg 1983; 198:63-4.
4. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10 year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 2004; 22:3668-76.
5. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-9.
6. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999; 230:453-63; discussion 463-5.
7. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:976-83.
8. Bleicher RJ, Essner R, Foshag LJ, et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003; 21:1326-31.
9. Jacobs IA, Chang CK, DasGupta TK, Salti GI. Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanoma. Ann Surg Oncol 2003; 10:558-61.
10. Bedrosian I, Faries MB, Guerry DT, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol 2000; 7:262-7.
11. Kesmodel SB, Karakousis GC, Botbyl JB, al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005; 12:449-58.
12. Agnese DM, Abdessalam SF, Burak WE Jr, et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 2003; 134:542-7; discussion 547-8.
13. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-34.
14. Steinberg D, Colla P. CART: Tree-Structured Non-Parametric Data Analysis. San Diego: Salford Systems, 1995.
15. Wagner JD, Gordon MS, Chuang TY, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 2000; 89:453-62.
16. Slingluff CL Jr, Vollmer RT, Reintgen DS, Seigler HF. Lethal "thin" malignant melanoma. Identifying patients at risk. Ann Surg 1988; 208:150-61.
17. Leiter U, Buettner PG, Eigentler TK, Garbe C. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the German Dermatological Society. J Clin Oncol 2004; 22:3660-7.
18. McKinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 2003; 98:1223-31.
19. Mansson-Brahme E, Carstensen J, Erhardt K, et al. Prognostic factors in thin cutaneous malignant melanoma. Cancer 1994; 73:2324-32.
20. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97:1488-98.
21. Corsetti RL, Allen HM, Wanebo HJ. Thin < or = 1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy. Ann Surg Oncol 2000; 7:456-60.
22. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004; 11:247-58.
23. Nguyen CL, McClay EF, Cole DJ, et al. Melanoma thickness and histology predict sentinel lymph node status. Am J Surg 2001; 181:8-11.
24. McMasters KM, Wong SL, Edwards MJ, et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 2001; 130:151-6.
25. Rousseau DL Jr, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 2003; 10:569-74.
26. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, et al. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol 1998; 134:983-7.
27. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res 2003; 36:347-50.
28. Olah J, Gyulai R, Korom I, et al. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol 2003; 149:662-3.
29. Stitzenberg KB, Groben PA, Stern SL, et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or = 1.0 mm). Ann Surg Oncol 2004; 11:900-6.
30. Thompson JF, Shaw HM. Should tumor mitotic rate and patient age, as well as tumor thickness, be used to select melanoma patients for sentinel node biopsy? Ann Surg Oncol 2004; 11:233-5.
31. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000; 7:469-74.
32. Joseph E, Brobeil A, Glass F, et al. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol 1998; 5:119-25.